CA2769847C - Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor - Google Patents

Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor Download PDF

Info

Publication number
CA2769847C
CA2769847C CA2769847A CA2769847A CA2769847C CA 2769847 C CA2769847 C CA 2769847C CA 2769847 A CA2769847 A CA 2769847A CA 2769847 A CA2769847 A CA 2769847A CA 2769847 C CA2769847 C CA 2769847C
Authority
CA
Canada
Prior art keywords
pyrimido
pyrrolo
dione
dihydro
quinoxaline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2769847A
Other languages
English (en)
French (fr)
Other versions
CA2769847A1 (en
Inventor
Alan S. Verkman
Lukmanee Tradtrantip
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2769847A1 publication Critical patent/CA2769847A1/en
Application granted granted Critical
Publication of CA2769847C publication Critical patent/CA2769847C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2769847A 2009-08-10 2010-08-10 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor Active CA2769847C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23274109P 2009-08-10 2009-08-10
US61/232,741 2009-08-10
PCT/US2010/045052 WO2011019737A1 (en) 2009-08-10 2010-08-10 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor

Publications (2)

Publication Number Publication Date
CA2769847A1 CA2769847A1 (en) 2011-02-17
CA2769847C true CA2769847C (en) 2019-01-08

Family

ID=43586433

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2769847A Active CA2769847C (en) 2009-08-10 2010-08-10 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor

Country Status (6)

Country Link
US (1) US8609661B2 (OSRAM)
EP (1) EP2464354B1 (OSRAM)
CN (1) CN102695510A (OSRAM)
CA (1) CA2769847C (OSRAM)
IN (1) IN2012DN00719A (OSRAM)
WO (1) WO2011019737A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48842E1 (en) * 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
AP2015008539A0 (en) * 2012-12-19 2015-06-30 Novartis Ag Tricyclic compounds for inhibiting the CFTR channel
CA2895656A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
CN114948966B (zh) * 2022-04-27 2023-06-20 南京鼓楼医院 一种小分子抑制剂在制备治疗多发性硬化和脓毒症的药物中的应用
CN115998763A (zh) * 2023-01-17 2023-04-25 暨南大学 氯离子及靶向氯离子通道的化合物在调控铁死亡中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751969B1 (fr) 1996-08-01 1998-12-04 Centre Nat Rech Scient Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
GB9626643D0 (en) * 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
CN1960966A (zh) 2004-03-30 2007-05-09 加利福尼亚大学董事会 含酰肼cftr抑制剂化合物及其用途
US7563793B2 (en) * 2004-12-20 2009-07-21 Wyeth Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents
JP2010523579A (ja) * 2007-04-02 2010-07-15 インスティテュート フォア ワンワールド ヘルス Ｃｆｔｒ阻害剤化合物およびそれらの使用
ES2422741T3 (es) 2007-12-13 2013-09-13 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP2011517674A (ja) 2008-03-25 2011-06-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性線維症膜コンダクタンス制御因子の水溶性小分子阻害剤
EP2288592A2 (en) 2008-04-04 2011-03-02 The Regents of the University of California Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor

Also Published As

Publication number Publication date
CN102695510A (zh) 2012-09-26
WO2011019737A1 (en) 2011-02-17
IN2012DN00719A (OSRAM) 2015-06-19
EP2464354A1 (en) 2012-06-20
EP2464354B1 (en) 2015-04-01
EP2464354A4 (en) 2013-03-27
CA2769847A1 (en) 2011-02-17
US8609661B2 (en) 2013-12-17
US20120208822A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
CA2769847C (en) Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US20240067600A1 (en) SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)
KR101600634B1 (ko) 항암제
CA2903103C (en) Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
ES2250377T3 (es) Moleculas organicas pequeñas reguladoras de la proliferacion celular.
USRE48842E1 (en) Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
TWI423978B (zh) 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（二）
WO2009120803A2 (en) Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
CN103172648B (zh) 三杂环衍生物、制备方法及应用
MX2014013294A (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
CN108947952A (zh) 2-取代氨基-5-三氟甲基-8-硝基苯并（硫代）吡喃-4-酮类化合物及其制备方法和用途
US9303042B2 (en) Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors
CN112694461B (zh) 色满酮类化合物及其制备方法和用途
KR101459720B1 (ko) 세로토닌 5-ＨＴ6 저해 활성을 갖는 5-설포닐아미노-5,6-다이하이드로-1Ｈ-피라졸로[3,4-ｃ]피리딘-7(4Ｈ)-온 화합물
KR101773575B1 (ko) 테트라하이드로벤조티오펜 유도체, 이의 제조방법 및 이를 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
WO2008109936A1 (en) Steroidal compounds
JPS6293284A (ja) メトキシフエニルアルキルチオアゾ−ル化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160729